Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaaki Mori

Showing results (1-10 of 303) with videos related to

Pageof 31
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 28, 2004
[Genes, structures, and biosynthesis of urotensin II]Masaaki Mori
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 5, 2013
Nationwide survey of treatment for pediatric patients with invasive fungal infections in JapanMasaaki Mori
Pediatrics International : Official Journal of the Japan Pediatric Society|October 22, 2020
What are the main revised points in the 6th diagnostic guidelines for Kawasaki disease?Masaaki Mori
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 28, 2004
[Development of therapeutic agents related to urotensin II]Masaaki Mori
Immunological Medicine|April 3, 2019
Pediatric rheumatic diseases: a review regarding the improvement of long-term prognosis and the transition to adultsMasaaki Mori
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 16, 2011
[Steroid therapy]Masaaki Mori
Children (Basel, Switzerland)|August 29, 2024
Overview of the Treatment Goal, the Method of Evaluating Disease Activity/Physical Function, Activities of Daily Living, and Traditional Care for Systemic or Articular Juvenile Idiopathic Arthritis in JapanMasaaki Mori
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|July 20, 2007
[Discovery of neuropeptide W and neuropeptide B]Masaaki Mori
Pediatrics International : Official Journal of the Japan Pediatric Society|February 9, 2019
In order to identify immunocompromised patients, what should general pediatricians do first?Masaaki Mori
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 19, 2014
[Plasma exchange therapy]Masaaki Mori
Pageof 31

Showing results (1-10 of 303) with videos related to

Sort By:
Pageof 31
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 28, 2004
[Genes, structures, and biosynthesis of urotensin II]Masaaki Mori
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 5, 2013
Nationwide survey of treatment for pediatric patients with invasive fungal infections in JapanMasaaki Mori
Pediatrics International : Official Journal of the Japan Pediatric Society|October 22, 2020
What are the main revised points in the 6th diagnostic guidelines for Kawasaki disease?Masaaki Mori
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 28, 2004
[Development of therapeutic agents related to urotensin II]Masaaki Mori
Immunological Medicine|April 3, 2019
Pediatric rheumatic diseases: a review regarding the improvement of long-term prognosis and the transition to adultsMasaaki Mori
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 16, 2011
[Steroid therapy]Masaaki Mori
Children (Basel, Switzerland)|August 29, 2024
Overview of the Treatment Goal, the Method of Evaluating Disease Activity/Physical Function, Activities of Daily Living, and Traditional Care for Systemic or Articular Juvenile Idiopathic Arthritis in JapanMasaaki Mori
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|July 20, 2007
[Discovery of neuropeptide W and neuropeptide B]Masaaki Mori
Pediatrics International : Official Journal of the Japan Pediatric Society|February 9, 2019
In order to identify immunocompromised patients, what should general pediatricians do first?Masaaki Mori
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 19, 2014
[Plasma exchange therapy]Masaaki Mori
Pageof 31